Related references
Note: Only part of the references are listed.Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management
Stephen M. Ansell
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry
Mary Ann Anderson et al.
BMC MEDICAL RESEARCH METHODOLOGY (2022)
Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy
Anita J. Kumar et al.
JOURNAL OF GERIATRIC ONCOLOGY (2021)
Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma
Anna R. Hayden et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century
Dianne Pulte et al.
BLOOD CANCER JOURNAL (2020)
Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality
Andrew M. Evens et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study
Jorne Lionel Biccler et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Management of older Hodgkin lymphoma patients
Andrew M. Evens et al.
Hematology-American Society of Hematology Education Program (2019)
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations
Catherine S. Diefenbach et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations
Catherine S. Diefenbach et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study
James R. Cerhan et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2017)
Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction
Ezra Hahn et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Discrimination and Calibration of Clinical Prediction Models Users' Guides to the Medical Literature
Ana Carolina Alba et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
Sally F. Barrington et al.
BLOOD (2016)
Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia
Greg Hapgood et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
Patrice Carde et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816
Oliver W. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
Francesco Merli et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Peter Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
Karel G. M. Moons et al.
ANNALS OF INTERNAL MEDICINE (2015)
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era
Catherine S. Diefenbach et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial
N. Mounier et al.
ANNALS OF ONCOLOGY (2014)
Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)
Leo I. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era
Alden A. Moccia et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi
Teodoro Chisesi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Simonetta Viviani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Multiple imputation using chained equations: Issues and guidance for practice
Ian R. White et al.
STATISTICS IN MEDICINE (2011)
The Importance of Testing PET-Directed Therapy in Patients with Hodgkin Lymphoma
James O. Armitage
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2011)
Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
Peter J. Hoskin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients
Hermann Brenner et al.
BLOOD (2008)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
Treatment of Hodgkin lymphoma: the past, present, and future
Andrew M. Evens et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M. Evens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Share Paper
